Biotie Therapies - Annual report/ annual accounts

Biotie Therapies Corp. Annual Report 2008 published

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE April 27, 2009 at 3.15
p.m.


Biotie Therapies Corp. Annual Report 2008 published

Biotie Therapies Corp. Annual Report for 2008 has been published. The
Annual Report can be downloaded in pdf format from the Biotie website
at www.biotie.com.

The printed version of the Annual Report can be ordered from the
company, telephone +358 2 274 8900, e-mail virve.nurmi@biotie.com or
address Tykistökatu 6, 20520 Turku, Finland.



Turku April 27, 2009

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail:

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com


Biotie Therapies Corp.
Biotie is a drug discovery and development company focused on central
nervous system and inflammatory diseases. It has a broad range of
innovative small molecule and biological drug candidates at different
stages of clinical and pre-clinical development. Biotie's products
address diseases with high unmet medical need and significant market
potential, including addiction and psychotic disorders, rheumatoid
arthritis, psoriasis and chronic obstructive pulmonary disease
(COPD). The most advanced product, nalmefene for alcohol dependence,
is currently in phase III clinical development by licensing partner
H. Lundbeck A/S.

Attachments:

Biotie Annual Report 2008.pdf